

Takeshi Kotake

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6905758/publications.pdf>

Version: 2024-02-01

8
papers

67
citations

1684188
5
h-index

1720034
7
g-index

8
all docs

8
docs citations

8
times ranked

145
citing authors

#	ARTICLE	IF	CITATIONS
1	Early diagnosis and bevacizumab combined with chemotherapy improved pulmonary tumor thrombotic microangiopathy with lung adenocarcinoma: A case report. <i>Current Problems in Cancer Case Reports</i> , 2022, 7, 100173.	0.1	0
2	Downregulated ATP6V1B1 expression acidifies the intracellular environment of cancer cells leading to resistance to antibody-dependent cellular cytotoxicity. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 817-830.	4.2	10
3	Prevalence and risk factors of hepatitis B virus reactivation in patients with solid tumors with resolved HBV infection. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 63-68.	1.1	9
4	Clinical Predictive Factors for the Efficacy of Everolimus in Patients With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: A Multicenter Retrospective Cohort Study in Japan. <i>Breast Cancer: Basic and Clinical Research</i> , 2019, 13, 117822341882513.	1.1	1
5	Gene expression profile of peripheral blood mononuclear cells may contribute to the identification and immunological classification of breast cancer patients. <i>Breast Cancer</i> , 2019, 26, 282-289.	2.9	17
6	Phase I study of primary treatment with 5-FU, oxaliplatin, irinotecan, levofolinate, and panitumumab combination chemotherapy in patients with advanced/recurrent colorectal cancer involving the wild-type RAS gene: the JACCRO CC-14 study. <i>International Journal of Clinical Oncology</i> , 2018, 23, 490-496.	2.2	10
7	Abemaciclib for the treatment of breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 517-524.	1.8	17
8	First report of a Japanese phase I study of triplet plus bevacizumab for chemotherapy-naive metastatic colorectal cancer (J1-TRIBE study). <i>Cancer Treatment Communications</i> , 2015, 4, 75-80.	0.4	3